| Pharmaceutical composition containing sepiapterin and its use |
2023-5-30 |
2023-8-22 |
|
| Heterocyclic and heteroaryl compounds for treating Huntington's disease |
2023-5-23 |
2023-6-15 |
|
| Methods for modulating rna splicing |
2023-5-12 |
2023-8-31 |
|
| PROCESS FOR PRODUCTION OF α-TOCOTRIENOL AND DERIVATIVES |
2023-3-31 |
2023-5-25 |
|
| Crystal form of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid |
2023-3-13 |
2023-6-06 |
|
| Methods for Treating Huntington’s Disease |
2023-2-17 |
2023-6-29 |
|
| Inhibitors of nlrp3 |
2023-2-16 |
2023-8-24 |
|
| Carboline compounds and use thereof |
2022-12-30 |
2023-8-03 |
|
| Improved methods for enriching alpha-tocotrienol from mixed tocol compositions |
2022-10-11 |
2022-12-02 |
|
| Compositions for an orally active 1,2,4-oxadiazole for the treatment of disease |
2022-10-11 |
2023-7-13 |
|
| Compounds for treating huntington's disease |
2022-10-03 |
2022-12-01 |
|
| Pharmaceutical composition of sepiapterin |
2022-9-29 |
2023-4-06 |
|
| Polymorphs of sepiapterin and salts thereof |
2022-9-22 |
2023-1-10 |
|
| Methods for treating neurogenerative diseases |
2022-9-06 |
2023-3-16 |
|
| Methods for treating neurogenerative diseases |
2022-9-06 |
2023-3-16 |
|
| Methods for treating neurogenerative diseases |
2022-9-06 |
2023-3-16 |
|
| 1,2,4-triazine derivatives useful as inhibitors of nlrp3 |
2022-8-24 |
2023-3-02 |
|
| Inhibitors of nlrp3 |
2022-8-24 |
2023-3-02 |
|
| Heteroaryl compounds for treating huntington's disease |
2022-7-29 |
2023-2-02 |
|
| Heteroaryl compounds for treating Huntington's disease |
2022-7-28 |
2022-8-25 |
|
| Methods for synthesis of racemic, scalemic, and chiral alpha-tocotrienol … |
2022-7-27 |
2023-2-02 |
|
| Recombinant reelin gene therapy |
2022-7-15 |
2023-1-19 |
|
| Recombinant reelin gene therapy |
2022-7-15 |
2023-9-07 |
|
| 2-substituted amino-naphth (1,2-d) imidazol-5-one compounds of pharmaceutically … |
2022-7-11 |
2023-4-13 |
|
| Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5- … |
2022-7-08 |
2023-1-26 |
|
| Compounds to treat familial dysautonomia |
2022-6-10 |
2022-7-29 |
|
| Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl- … |
2022-6-10 |
2022-8-09 |
|
| 4-(p-quinolyl)-2-hydroxybutanamide derivative for treatment of mitochondrial … |
2022-5-02 |
2022-6-23 |
|
| Compounds for treating huntington's disease |
2022-4-18 |
2022-8-11 |
|
| Regulation of transgene expression using a small molecule inducible splicing … |
2022-3-25 |
2022-9-29 |
|
| Methods for treating hyperphenylalaninemia |
2022-3-21 |
2022-5-01 |
|
| Methods for treating glioblastomas with sepiapterin |
2022-2-09 |
2022-8-18 |
|
| Methods for treating glioblastomas with sepiapterin |
2022-2-09 |
2023-9-07 |
|
| Methods for treating covid-19 with sepiapterin |
2022-2-09 |
2022-8-18 |
|
| Use of sepiapterin and metabolites thereof to treat radiation exposure |
2022-2-03 |
2022-4-01 |
|
| Compounds for treating spinocerebellar ataxia type 3 |
2022-2-02 |
2022-8-11 |
|
| Methods for treating spinocerebellar ataxia type 3 |
2022-2-02 |
2022-8-11 |
|
| Methods for treating spinocerebellar ataxia type 3 |
2022-2-02 |
2022-8-11 |
|
| Tablet for use in treating huntington's disease and method of making the same |
2022-1-28 |
2022-5-19 |
|
| 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and … |
2022-1-25 |
2022-7-14 |
|
| 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and … |
2022-1-25 |
2023-9-05 |
2023-9-05 |
| Methods and compositions for treatment of inflammation and oxidative stress |
2021-11-29 |
2022-8-18 |
|
| Tablet for use in treating huntington's disease and method of making the same |
2021-11-15 |
2022-8-01 |
|
| Tablet for treating huntington's disease and preparation method thereof |
2021-11-12 |
2023-8-22 |
|
| TABLET FOR USE IN THE TREATMENT OF HUNTINGTON'S DISEASE AND METHOD OF PRODUCING … |
2021-11-12 |
2023-2-08 |
|
| Novel rna transcript |
2021-11-11 |
2023-6-15 |
|
| Substituted reverse pyrimidine bmi-1 inhibitors |
2021-11-10 |
2022-3-03 |
|
| Compounds for treating huntington's disease |
2021-11-09 |
2022-1-01 |
|
| Vector and method to treat angelman syndrome |
2021-10-19 |
2022-2-28 |
|
| Method for treating nonsense mutation mediated duchenne muscular dystrophy in … |
2021-10-06 |
2021-12-01 |
|
| Polymorphic form of sepiapterin |
2021-9-27 |
2022-3-17 |
|
| Combinations useful in a method for treating sarcoma |
2021-9-23 |
2021-10-31 |
|
| Risdiplam or a pharmaceutically acceptable salt thereof |
2021-9-15 |
2021-10-25 |
|
| FORM OF A COMPOUND HAVING ENHANCED BIOAVAILABILITY AND FORMULATIONS THEREOF |
2021-9-09 |
2021-11-18 |
|
| Method for treating a multiple myeloma |
2021-8-23 |
2021-10-31 |
|
| Thioene [3,2-b] pyridin-7-amine compounds to treat familial dysautonomia |
2021-8-12 |
2021-8-30 |
|
| Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones |
2021-8-11 |
2022-5-05 |
|
| Methods of administering deflazacort therapy |
2021-8-04 |
2021-11-25 |
|
| Method for treating an acute myeloid leukemia |
2021-7-13 |
2021-8-31 |
|
| Pharmaceutical compositions and salts of 1,2,4-oxadiazole benzoic acid |
2021-7-05 |
2021-10-14 |
|
| Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amino 1,4- … |
2021-6-25 |
2021-10-14 |
|
| Redox-active therapeutics for treatment of mitochondrial diseases and other … |
2021-5-28 |
2022-2-24 |
|
| Quantification of dystrophin |
2021-5-24 |
2021-12-02 |
|
| Dhodh inhibitor for the treatment of covid-19 |
2021-5-07 |
2023-6-08 |
|
| Treatment of oxidative stress disorders including contrast nephropathy, … |
2021-3-29 |
2021-10-21 |
|
| Optically resolved trolox intermediate and method for producing same |
2021-2-19 |
2023-1-26 |
|
| BIO-AVAILABLE ORAL PHARMACEUTICAL FORMS |
2021-2-19 |
2021-3-31 |
|
| Method for treating pancreatic cancer |
2021-2-10 |
2021-4-29 |
|
| Methods for treating parkinson's disease with sepiapterin |
2021-1-22 |
2021-7-29 |
|
| Rna splicing modulation |
2021-1-04 |
2022-11-09 |
|
| Pharmaceutically acceptable sepiapterin salts |
2020-12-29 |
2021-4-08 |
|
| Pharmaceutically acceptable salts of sepiapterin |
2020-12-23 |
2023-4-26 |
|
| Compounds for treating spinal muscular atrophy |
2020-11-16 |
2021-5-20 |
|
| Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation … |
2020-10-23 |
2021-2-11 |
|
| 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and … |
2020-10-16 |
2021-4-22 |
|
| Compounds for treating spinal muscular atrophy |
2020-10-05 |
2021-9-09 |
|
| Compounds for treating huntington's disease |
2020-9-22 |
2020-11-30 |
|
| Treatment of methylmalonic aciduria, isovaleric aciduria, and other organic … |
2020-9-17 |
2021-5-20 |
|
| Treatment of pervasive developmental disorders with redox-active therapeutics |
2020-8-10 |
2021-5-06 |
|
| Compounds for use in treating huntington's disease |
2020-7-09 |
2021-1-14 |
|
| Method of inhibiting or reducing a coronaviridae virus infection |
2020-6-23 |
2020-10-08 |
|
| Naphthoquinone derivatives for treatment of oxidative stress disorders |
2020-6-13 |
2023-8-30 |
2023-8-30 |
| PROCESSES FOR THE PREPARATION OF 1,2,4-OXADIAZOLE BENZOIC ACIDS |
2020-5-12 |
2021-11-10 |
|
| Methods for modulating RNA splicing |
2020-4-13 |
2023-3-14 |
2023-3-14 |
| Dispersible tablet composition |
2020-4-10 |
2020-10-15 |
|
| Therapeutic combinations for use in treating a muscular dystrophy |
2020-3-18 |
2020-9-24 |
|
| METHOD FOR TREATMENT OF A MULTIPLE MELOMA |
2020-2-26 |
2021-10-19 |
|
| THIENO[3,2-B]PYRIDIN-7-AMINE COMPOUNDS FOR THE TREATMENT OF FAMILY DYSAUTONOMY |
2020-2-10 |
2021-10-05 |
|
| Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia |
2020-2-10 |
2022-5-05 |
|
| Dhodh inhibitor for use in treating hematologic cancers |
2020-1-16 |
2020-3-31 |
|
| METHOD TO TREAT ACUTE MYELOID LEUKEMIA |
2020-1-15 |
2021-9-21 |
|
| Methods to treat huntington's disease. |
2019-12-20 |
2020-7-17 |
|
| Methods to treat huntington's disease. |
2019-12-20 |
2020-7-17 |
|
| Methods for modifying rna splicing |
2019-11-29 |
2020-1-30 |
|
| Methods for treating epilepsy |
2019-11-07 |
2020-6-18 |
|
| Processes for the preparation of substituted tetrahydro beta-carbolines |
2019-9-24 |
2021-3-16 |
2021-3-16 |
| Heteroaryl compounds for treating huntington's disease |
2019-6-25 |
2021-5-05 |
|
| Medicinal agent and beverage/food for preventing cerebral dysfunction and … |
2019-6-18 |
2020-1-09 |
|
| compositions and methods for increasing plasma exposure of tetrahydrobiopterin |
2019-5-30 |
2021-2-23 |
|
| Sepiapterin Methods for Increasing Plasma Exposure |
2019-5-30 |
2021-9-27 |
|